Nuclear Medicine Unit, Hematology-Oncology and Laboratory Medicine Department, Azienda Ospedaliero-Universitaria di Bologna Policlinico S Orsola-Malpighi, University of Bologna, Bologna, Italy.
J Nucl Med. 2011 Jun;52(6):886-90. doi: 10.2967/jnumed.111.088328. Epub 2011 May 13.
The aim of our retrospective study was to assess the incidence of increased uptake of (68)Ga-DOTANOC in the head of the pancreas among a large population of patients with extrapancreatic neuroendocrine tumors studied with serial (68)Ga-DOTANOC PET/CT.
Patients who had undergone at least two (68)Ga-DOTANOC PET/CT studies over time were included. Uptake in the head of the pancreas was measured and compared with uptake in normal liver parenchyma (target-to-liver ratio). Patients were followed up for 6-24 mo.
We reviewed 245 studies performed on 100 patients and classified the pancreatic uptake as either diffuse or focal. Twenty-three patients (66 scans) showed diffuse uptake; 8 patients (16 scans) showed focal uptake. None of these 31 patients had negative findings on their subsequent scans, and vice versa. During follow-up, localization of neuroendocrine tumors in the pancreas was not suspected in any patient.
Focal and diffuse uptake of (68)Ga-DOTANOC in the head of the pancreas occurred, respectively, in 23% and 8% of the patients. The main finding of our study was that increased pancreatic uptake was stable over time.
本回顾性研究旨在评估在接受系列（68）Ga-DOTANOC PET/CT 检查的胰腺外神经内分泌肿瘤患者中，（68）Ga-DOTANOC 在胰头部摄取增加的发生率。
纳入至少进行过两次（68）Ga-DOTANOC PET/CT 检查的患者。测量胰头部摄取并与正常肝实质摄取（靶肝比）进行比较。对患者进行 6-24 个月的随访。
我们回顾了 100 名患者的 245 项研究，并将胰头摄取分为弥漫性或局灶性。23 名患者（66 次扫描）表现为弥漫性摄取；8 名患者（16 次扫描）表现为局灶性摄取。这些 31 名患者在随后的扫描中均无阴性发现，反之亦然。在随访期间，没有患者怀疑胰腺内神经内分泌肿瘤的定位。
分别有 23%和 8%的患者出现（68）Ga-DOTANOC 在胰头部的弥漫性和局灶性摄取。本研究的主要发现是胰头摄取随时间稳定增加。
